Northern Capital Management (Wisconsin)’s Tempest Therapeutics TPST Stock Holding History

Northern Capital Management (Wisconsin)’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-31	Closed	-$129K	–	158
2017 Q3	$129K	Hold	31	–	–	0.04%	150
2017 Q2	$143K	Hold	31	–	–	0.05%	147
2017 Q1	$172K	Buy	31 +15	+94%	+$69.9K	0.07%	139
2016 Q4	$73K	Buy	16 +11	+220%	+$137K	0.03%	139
2016 Q3	$106K	Sell	5 -5	-50%	-$90.5K	0.05%	136
2016 Q2	$158K	Buy	10 +4	+67%	+$91.4K	0.07%	133
2016 Q1	$179K	Buy	6 +1	+20%	+$21.1K	0.08%	139
2015 Q4	$146K	Buy	+5	New	+$165K	0.06%	145

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Capital Management (Wisconsin)'s TPST Position: Q4 2017 in Review

Northern Capital Management (Wisconsin) sold out of Tempest Therapeutics (TPST) in Q4 2017, closing a stake of 31 shares — an estimated $129K sold.

Northern Capital Management (Wisconsin) first reported a position in TPST in Q4 2015 and held it in 8 quarters. The position peaked at $179K in Q1 2016. 50 funds tracked by Wall St. Rank hold TPST as of Q4 2017.

Northern Capital Management (Wisconsin) reported no remaining Tempest Therapeutics position as of Q4 2017 after selling out during the quarter.
Northern Capital Management (Wisconsin) sold 31 Tempest Therapeutics shares in Q4 2017, an estimated $129K.
Northern Capital Management (Wisconsin) first reported a position in Tempest Therapeutics in Q4 2015 and held it in 8 quarters.
Northern Capital Management (Wisconsin)'s Tempest Therapeutics position peaked at $179K in Q1 2016.
50 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2017.

Based on Northern Capital Management (Wisconsin)'s 13F filing for Q4 2017, filed 30 Jan 2018.